Literature DB >> 31857946

Molecular targeted therapies in non-small cell lung cancer: where we are.

Lucio Crinò1, Angelo Delmonte1.   

Abstract

Entities:  

Year:  2019        PMID： 31857946      PMCID： PMC6894989          DOI： 10.21037/tlcr.2019.11.13

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  7 in total

1.  Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Authors:  Deepa Rangachari; Norihiro Yamaguchi; Paul A VanderLaan; Erik Folch; Anand Mahadevan; Scott R Floyd; Erik J Uhlmann; Eric T Wong; Suzanne E Dahlberg; Mark S Huberman; Daniel B Costa
Journal:  Lung Cancer       Date:  2015-02-04       Impact factor: 5.705

Review 2.  Resisting Resistance: Targeted Therapies in Lung Cancer.

Authors:  Jessica J Lin; Alice T Shaw
Journal:  Trends Cancer       Date:  2016-07

Review 3.  Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Cancer Discov       Date:  2016-03-11       Impact factor: 39.397

4.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

5.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

6.  Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors:  I Bernard Weinstein
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

7.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245
  7 in total
  1 in total

1.  Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line.

Authors:  Zhiyong He; Fusheng Gong; Jinrong Liao; Qiang Wang; Ying Su; Chao Chen; Jinghui Lin; Ren-Jang Lin
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.